Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

5/20/24 12:40:14 AM ET

$INVA

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $INVA alert in real time by email

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization
China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resistant bacterial strains
In China, it is estimated there are approximately 300,000 cases of Acinetobacter infections and approximately 74% of them are carbapenem-resistant

Get the next $INVA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INVA
$ZLAB

Company	Date	Price Target	Rating	Analyst
Innoviva Inc. $INVA	6/18/2024		Overweight	Cantor Fitzgerald
Zai Lab Limited $ZLAB	12/14/2023	$47.50	Overweight	Morgan Stanley
Zai Lab Limited $ZLAB	8/10/2023	$70.00	Overweight	Cantor Fitzgerald
Innoviva Inc. $INVA	7/20/2022	$16.00	Neutral	Goldman
Zai Lab Limited $ZLAB	3/2/2022	$194.00 → $102.00	Outperform	SVB Leerink
Innoviva Inc. $INVA	2/23/2022	$10.00 → $12.00	Underweight	Morgan Stanley
Innoviva Inc. $INVA	2/11/2022	$28.00	Buy	EF Hutton
Zai Lab Limited $ZLAB	1/21/2022	$64.00	Outperform	Macquarie

More analyst ratings

$INVA
$ZLAB
Press Releases

Fastest customizable press release news feed in the world

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
KarXT demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo (p=0.0014) Trial also met all secondary endpoints, demonstrating statistically significant reductions in positive and negative symptoms of schizophrenia, as measured by the PANSS positive subscale, PANSS negative subscale and PANSS negative Marder factor score KarXT has a tolerable safety profile with no new or unexpected safety signals Based on these results, Zai is moving swiftly to submit New Drug Application (NDA) to China's National Medical Products Administration (NMPA) in early 2025 Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced positive
10/29/24 7:30:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
-- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK) and safety profile support continued evaluation of ZL-1310 as a single agent and in combination for the treatment of extensive-stage SCLC in recurrent and first-line therapy -- Zai Lab to host conference call and webcast to discuss data on October 24, 2024, at 8:30 a.m. ET, following presentation of the data at ENA Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC)
10/24/24 5:15:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Zai Lab Announces Participation in November and December Investor Conferences
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that members of the Company's senior management team will participate in the following investor conferences in November and December 2024: Goldman Sachs APAC Healthcare Corporate Day 2024 Time: November 5-8, 2024 Location: Hong Kong, Hong Kong Jefferies London Healthcare Conference Fireside Chat: Tuesday, November 19, 2024,1:30 p.m. GT Location: Aldwych, London Citi's 2024 Global Healthcare Conference Time: December 3-5, 2024 Location: Miami, Florida About Zai Lab Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focu
10/18/24 7:30:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
-- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK) and safety profile support continued evaluation of ZL-1310 as a single agent and in combination for the treatment of extensive-stage SCLC in recurrent and first-line therapy -- Zai Lab to host conference call and webcast to discuss data on October 24, 2024, at 8:30 a.m. ET, following presentation of the data at ENA Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC)
10/24/24 5:15:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
Company to host conference call and webcast on October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT), following plenary oral presentation of data at the EORTC-NCI-AACR Symposium (ENA) 2024 Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company's investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Compan
10/17/24 8:00:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
- Company to Host Conference Call and Webcast on November 12, 2024, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that it will report financial results for the third quarter of 2024 and recent corporate updates, before the opening of the U.S. equity markets on Tuesday, November 12, 2024. The Company will host a live conference call and webcast on the same date, at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration Link: ht
10/16/24 7:30:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care

$INVA
$ZLAB
Leadership Updates

Live Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in
6/11/24 4:05:00 PM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Innoviva Appoints Stephen Basso as Chief Financial Officer
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind
8/25/23 4:52:00 PM ET
$INVA
Biotechnology: Pharmaceutical Preparations
Health Care
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t
7/11/23 8:00:00 AM ET
$ARMP
$INVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

Chat with this insight

Recent Analyst Ratings for $INVA$ZLAB

$INVA$ZLAB Press Releases

Fastest customizable press release news feed in the world

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces Participation in November and December Investor Conferences

$INVA$ZLAB Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

SEC Form SC 13G filed by Innoviva Inc.

SEC Form SC 13D filed by Innoviva Inc.

$INVA$ZLAB Financials

Live finance-specific insights

$INVA$ZLAB Market Insights

Live Market Insights

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $38

$INVA$ZLAB SEC Filings

SEC Form 144 filed by Zai Lab Limited

SEC Form 10-Q filed by Zai Lab Limited

Zai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$INVA$ZLAB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Innoviva

Morgan Stanley initiated coverage on Zai Lab with a new price target

Cantor Fitzgerald initiated coverage on Zai Lab with a new price target

$INVA$ZLAB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

$INVA$ZLAB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Chen Yajing converted options into 920 units of American Depositary Shares and sold $7,645 worth of American Depositary Shares (301 units at $25.40), increasing direct ownership by 4% to 15,161 units (SEC Form 4)

Director Gaynor Richard sold $48,750 worth of American Depositary Shares (2,500 units at $19.50), decreasing direct ownership by 5% to 46,568 units (SEC Form 4)

Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 975 shares, decreasing direct ownership by 2% to 45,615 units (SEC Form 4)

$INVA$ZLAB Leadership Updates

Live Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Innoviva Appoints Stephen Basso as Chief Financial Officer

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Recent Analyst Ratings for
$INVA
$ZLAB

$INVA
$ZLAB
Press Releases

$INVA
$ZLAB
Large Ownership Changes

$INVA
$ZLAB
Financials

$INVA
$ZLAB
Market Insights

$INVA
$ZLAB
SEC Filings

$INVA
$ZLAB
Analyst Ratings

$INVA
$ZLAB
Insider Purchases

$INVA
$ZLAB
Insider Trading

$INVA
$ZLAB
Leadership Updates